he maker of the popular painkiller Nurofen was ordered on Monday to remove some of its brands from store shelves in Australia.
The Federal Court ruled that UK-based drug giant Reckitt Benckiser made misleading claims about the pills’ effectiveness.
The court said Nurofen’s back pain, period pain, migraine pain, and tension headache brands were identical to standard Nurofen – despite being nearly double the price.
Ruling on complaints made by the fair trading regulator, the Australian Competition and Consumer Commission, the court found all the products contained the same amount of the active ingredient: 342 milligrams of ibuprofen lysine.
The drugs were “no more effective at treating the type of pain described on its packaging than any of the other Nurofen Specific Pain products”, the court ruled, according to an ACCC statement.
Full content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senate Democrats Urge DOJ Investigation into Alleged Big Oil Collusion
May 30, 2024 by
CPI
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI